PPCB Stock Analysis: Buy, Sell, or Hold?
PPCB - Propanc Biopharma, Inc. Common Stock
$2.26
1.19 (111.21%)
▲
5d:
+105.45%
30d:
+128.28%
90d:
+32.94%
WAIT
LOW Confidence
Analysis Updated: Aug 27, 2026 12:00 AM ET
Earnings: Oct 05, 2026
Get Alerted When PPCB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PPCB is 58.0% above its trading range ($1.43). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PPCB is 58.0% above its trading range ($1.43). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PPCB is currently trading at $2.26, which is considered extended relative to its 30-day fair value range of $1.01 to $1.43.
Technical Outlook: Technically, PPCB is in a uptrend. The price is approaching resistance at $1.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 111.2% recently.
Market Sentiment: PPCB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.52 (+42.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PPCB is in a uptrend. The price is approaching resistance at $1.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 111.2% recently.
Market Sentiment: PPCB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.52 (+42.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.01 -
$1.43
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+58.0% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+111.2%)
- BULLISH: Trading 42.1% below Wall St target ($1.52)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.01 -
$1.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.05
Resistance Level
$1.29
Current Trend
Uptrend
Technical data as of
Aug 26, 2026
Fundamental Context
Wall Street Target
$1.52
(+42.1%)
Share & Embed Analysis
Last updated: August 27, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PPCB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 29 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 43 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 37 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 56 HOLD |